

**From:** [Quinones, Edwin](#)  
**To:** [Mason, Steve](#); [McQuiddy, David](#); [Ruhl, Christopher](#); [Foster, Althea](#)  
**Cc:** [Harrison, Ben](#); [Peycke, Mark](#)  
**Subject:** FW: Corpus Christi Water Ban Incident and Indulin AA86 CBI  
**Date:** Friday, December 16, 2016 12:39:00 PM

---

FYI

---

**From:** Ryan Fisher [mailto:ryan.fisher@ingevity.com]  
**Sent:** Friday, December 16, 2016 12:26 PM  
**To:** Quinones, Edwin <quinones.edwin@epa.gov>  
**Cc:** Maureen Miller <maureen.miller@ingevity.com>; andrew.bickford@ingevity.com  
**Subject:** Re: Corpus Christi Water Ban Incident and Indulin AA86 CBI

Thank you for reaching out to me today.

I confirm your summary. If you share with your contractors (second paragraph), I understand they are covered by confidentiality obligations.

Please don't hesitate to contact me if we can further assist.

Regards

Ryan

Sent from my iPhone

On Dec 16, 2016, at 1:19 PM, Quinones, Edwin <[quinones.edwin@epa.gov](mailto:quinones.edwin@epa.gov)> wrote:

Hi Ryan,

It was a pleasure speaking with you today. As I mentioned during our call, I thought I would e-mail you with my understanding of our conversation concerning your client's (Ingevity) claim of CBI with respect to the ingredient list for the product known as Indulin AA-86. I've advised Wes McQuiddy at EPA Region 6's Houston Lab to make sure the Houston Lab treats the ingredient list as CBI and that EPA lab personnel not divulge that information to outside parties.

You and I also discussed my request for your client's permission to share the claimed CBI with our contractors who are helping us in this effort. You graciously granted my request for permission to share the information with our contractors.

I also added another request for permission to share the CBI with two third-parties, should the need arise, namely Valero and their subcontracted lab known as Inertek Lab. As I explained, Valero has offered to provide the EPA with analytical support and the use of Inertek Lab for our water sampling and testing methodology analyses. You also granted my request for permission to do so, which I greatly appreciate. Should we accept Valero's offer, I would envision the use of a confidentiality agreement with Valero and Inertek Lab when sharing the claimed CBI.

If the above meets with your understanding as well, would you please reply in the affirmative as soon as possible? I will then inform the EPA Program folks of Ingevity's permission to share the claimed CBI in the limited circumstances described above.

If you have any questions, please feel free to call or e-mail me.

Best regards,

Edwin Quinones  
Assistant Regional Counsel  
U.S. EPA Region 6, 6RC-S  
1445 Ross Ave.  
Dallas, TX 75202  
(214) 665-8035 Office  
(214) 665-6460 Fax  
[<image005.jpg>](#) [<image006.jpg>](#)

This electronic message contains information from Ingevity Corporation ([www.ingevity.com](http://www.ingevity.com)) or its affiliates, which may be confidential, privileged or otherwise protected from disclosure. The information is intended to be disclosed to and used by only the named recipient(s). If you are not the intended recipient, then your review, use, disclosure, printing, copying, or distribution of this message or its contents is prohibited. If you have received this message in error, please notify Ingevity immediately at [postmaster@ingevity.com](mailto:postmaster@ingevity.com), and delete the message from your system. Unless previously authorized in writing, this message does not constitute an offer, acceptance, or agreement of any kind. Sender is not liable for damage, errors or omissions related to or caused by transmission of this message. © Ingevity Corporation.